-DOCSTART- -X- O
Severe -X- _ O
and -X- _ O
fatal -X- _ O
viral -X- _ B-Patient
infections -X- _ I-Patient
remain -X- _ O
common -X- _ O
after -X- _ O
hematopoietic -X- _ O
stem -X- _ O
cell -X- _ O
transplantation. -X- _ O
Adoptive -X- _ O
transfer -X- _ O
of -X- _ O
cytotoxic -X- _ B-Intervention
T -X- _ I-Intervention
lymphocytes -X- _ I-Intervention
( -X- _ I-Intervention
CTLs -X- _ I-Intervention
) -X- _ I-Intervention
specific -X- _ O
for -X- _ O
Epsteinâ€“Barr -X- _ B-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
EBV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
cytomegalovirus -X- _ I-Patient
( -X- _ I-Patient
CMV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
and -X- _ I-Patient
adenoviral -X- _ I-Patient
antigens -X- _ I-Patient
can -X- _ O
treat -X- _ O
infections -X- _ O
that -X- _ O
are -X- _ O
impervious -X- _ O
to -X- _ O
conventional -X- _ O
therapies -X- _ O
, -X- _ O
but -X- _ O
broader -X- _ O
implementation -X- _ O
and -X- _ O
extension -X- _ O
to -X- _ O
additional -X- _ O
viruses -X- _ O
is -X- _ O
limited -X- _ O
by -X- _ O
competition -X- _ O
between -X- _ O
virus-derived -X- _ O
antigens -X- _ O
and -X- _ O
time-consuming -X- _ O
and -X- _ O
laborious -X- _ O
manufacturing -X- _ O
procedures. -X- _ O
We -X- _ O
now -X- _ O
describe -X- _ O
a -X- _ O
system -X- _ O
that -X- _ O
rapidly -X- _ O
generates -X- _ O
a -X- _ O
single -X- _ O
preparation -X- _ O
of -X- _ O
polyclonal -X- _ O
( -X- _ B-Intervention
CD4 -X- _ I-Intervention
( -X- _ I-Intervention
+ -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
CD8 -X- _ I-Intervention
( -X- _ I-Intervention
+ -X- _ I-Intervention
) -X- _ I-Intervention
) -X- _ I-Intervention
CTLs -X- _ I-Intervention
that -X- _ I-Intervention
is -X- _ I-Intervention
consistently -X- _ I-Intervention
specific -X- _ I-Intervention
for -X- _ I-Intervention
15 -X- _ I-Intervention
immunodominant -X- _ I-Intervention
and -X- _ I-Intervention
subdominant -X- _ I-Intervention
antigens -X- _ I-Intervention
derived -X- _ I-Intervention
from -X- _ I-Intervention
7 -X- _ I-Intervention
viruses -X- _ I-Intervention
( -X- _ I-Intervention
EBV -X- _ I-Intervention
, -X- _ I-Intervention
CMV -X- _ I-Intervention
, -X- _ I-Intervention
Adenovirus -X- _ I-Intervention
( -X- _ I-Intervention
Adv -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
BK -X- _ I-Intervention
, -X- _ I-Intervention
human -X- _ I-Intervention
herpes -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
HHV -X- _ I-Intervention
) -X- _ I-Intervention
-6 -X- _ I-Intervention
, -X- _ I-Intervention
respiratory -X- _ I-Intervention
syncytial -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
RSV -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
Influenza -X- _ I-Intervention
) -X- _ I-Intervention
that -X- _ O
commonly -X- _ O
cause -X- _ O
post-transplant -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
CTLs -X- _ B-Intervention
can -X- _ O
be -X- _ O
rapidly -X- _ O
produced -X- _ O
( -X- _ O
10 -X- _ O
days -X- _ O
) -X- _ O
by -X- _ O
a -X- _ O
single -X- _ O
stimulation -X- _ O
of -X- _ O
donor -X- _ O
peripheral -X- _ O
blood -X- _ O
mononuclear -X- _ O
cells -X- _ O
( -X- _ O
PBMCs -X- _ O
) -X- _ O
with -X- _ O
a -X- _ O
peptide -X- _ O
mixture -X- _ O
spanning -X- _ O
the -X- _ O
target -X- _ O
antigens -X- _ O
in -X- _ O
the -X- _ O
presence -X- _ O
of -X- _ O
the -X- _ O
potent -X- _ O
prosurvival -X- _ O
cytokines -X- _ O
interleukin-4 -X- _ O
( -X- _ O
IL4 -X- _ O
) -X- _ O
and -X- _ O
IL7. -X- _ O
This -X- _ O
approach -X- _ O
reduces -X- _ B-Outcome
the -X- _ I-Outcome
impact -X- _ I-Outcome
of -X- _ I-Outcome
antigenic -X- _ I-Outcome
competition -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
consequent -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
antigenic -X- _ I-Outcome
repertoire -X- _ I-Outcome
and -X- _ I-Outcome
frequency -X- _ I-Outcome
of -X- _ I-Outcome
virus-specific -X- _ I-Outcome
T -X- _ I-Outcome
cells. -X- _ I-Outcome
Our -X- _ O
approach -X- _ O
can -X- _ O
be -X- _ O
readily -X- _ O
introduced -X- _ O
into -X- _ O
clinical -X- _ O
practice -X- _ O
and -X- _ O
should -X- _ O
be -X- _ O
a -X- _ O
cost-effective -X- _ O
alternative -X- _ O
to -X- _ O
common -X- _ O
antiviral -X- _ O
prophylactic -X- _ O
agents -X- _ O
for -X- _ O
allogeneic -X- _ O
hematopoietic -X- _ O
stem -X- _ O
cell -X- _ O
transplant -X- _ O
( -X- _ O
HSCT -X- _ O
) -X- _ O
recipients -X- _ O
. -X- _ O

